Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

share with twitter share with LinkedIn share with facebook
09/18/2020 | 08:01pm EDT

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own.

Click here for more information: https://www.monteverdelaw.com/case/aimmune-therapeutics-inc. It is free and there is no cost or obligation to you.

The investigation focuses on whether Aimmune and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) failing to disclose all material information.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Juan E. Monteverde, Esq.
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-aimmune-therapeutics-inc--aimt-301134123.html

SOURCE Monteverde & Associates PC

© PRNewswire 2020

share with twitter share with LinkedIn share with facebook
10/21Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
10/19AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
10/19AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
10/15MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
10/15AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
10/13AIMMUNE THERAPEUTICS : Nestle announces results of tender offer for Aimmune Ther..
10/13GLOBAL MARKETS LIVE: U.S. banks beat expectations
10/13Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
10/13AIMMUNE THERAPEUTICS : shareholders accept $2 billion Nestle tender offer
09/18Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
More news